1.61
Inmune Bio Inc (INMB) 最新ニュース
Quantum Technology Meets Biotechnology: INmune Bio and Quantum Computing Inc. Team Up to Accelerate Drug Discovery - TheStreet
Full Transcript: INmune Bio Q2 2026 Earnings Call - Benzinga
TRex Bio, Inc. Common stock (TRXB) company profile and facts - Yahoo Finance UK
TRex Bio, Inc. Common stock (TRXB) stock price, news, quote and history - Yahoo Finance UK
INmune Bio stock heads into Maxim summit before Q3 results - AD HOC NEWS
Quantum Computing Inc. Announces Dirac-3S, Scaling to Nearly 10,000 Variables - Stock Titan
Form 4 INmune Bio Inc For: 23 September - Investing.com India
Form 4 INmune Bio Inc For: 23 September By Investing.com - Investing.com Canada
Form 4 INmune Bio Inc For: 23 September By Investing.com - Investing.com UK
Inmune Bio (INMB) gives director 3-year option grant - Stock Titan
Inmune Stock Price Forecast. Should You Buy INMB? - StockInvest.us
Inmune Bio (NASDAQ: INMB) grants 100,000 stock options to new director - Stock Titan
INmune Bio to Present at the H.C. Wainwright Global Investment Conference - Yahoo Finance
Inmune Bio stock steadies as investors await next data catalyst - ad-hoc-news.de
INmune Bio undervalued as Ebstrocel for RDEB ne... - Pluang
INmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory Alignment (NASDAQ:INMB) - Seeking Alpha
aTyr Pharma And 2 Other Penny Stocks With Promising Potential - Sahm
aTyr Pharma And 2 Other Penny Stocks With Promising Potential - simplywall.st
INmune Bio submits EU regulatory filings for Ebstrocel in RDEB By Investing.com - Investing.com Canada
INmune Bio submits EU regulatory filings for Ebstrocel in RDEB By Investing.com - Investing.com India
INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings - Yahoo Finance
INmune Bio submits EU regulatory filings for Ebstrocel in RDEB - Investing.com
INmune (INMB) Financial Results: EPS Comes in Above Forecast on the Day; Post-Earnings: The Stock Gains 1.72% in the Latest ReadingEarnings Analysis - dars.gov.et
INmune Bio (INMB) Climbs 4.33% to $2.17 as Traders Test Key Resistance at $2.28Put Spread Alert - dars.gov.et
Climb Bio, Inc. (CLYM): MPM BioImpact LLC reports 0% ownership in amendment - Stock Titan
INmune Bio Inc (INMB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
INmune Bio Advances Ebstrocel Regulatory Filings and Clinical Plans - sekbernews.id
INmune Bio (NASDAQ:INMB) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Q2 2026 INmune Bio Inc Earnings Call Transcript - GuruFocus
Earnings call transcript: INmune Bio posts narrower Q2 2026 loss, eyes filings - Investing.com South Africa
Earnings call transcript: INmune Bio posts narrower Q2 2026 loss, eyes filings - Investing.com Nigeria
INmune Bio (INMB) Q2 2026 Earnings Call Transcript - AOL.com
INmune Bio Inc (INMB) (Q2 2026) Earnings Call Highlights: Regula - GuruFocus
INmune Bio (INMB) Q2 2026 Earnings Call Transcript - The Globe and Mail
INmune Bio Inc (INMB) (Q2 2026) Earnings Call Highlights: Regulatory Wins and Strategic Focus ... - Yahoo Finance
INmune Bio, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
INmune Bio Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: INmune Bio posts narrower Q2 2026 loss, eyes filings - Investing.com
INmune Bio Q2 2026 Earnings: Tax-Credit Benefit Narrows Net Loss - TradingKey
INmune Bio (NASDAQ:INMB) Releases Quarterly Earnings Results, Beats Expectations By $0.16 EPS - MarketBeat
INMB: Ebstrocel nears global filings as financials strengthen and XPro advances in Alzheimer's - TradingView
INmune Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress - The Manila Times
Inmune Bio, Inc. Q2 2026: Revenue $0 Net loss $(1.27)M, EPS $(0.05) — 10-Q Summary - TradingView
INmune Bio Q2 net loss narrows on lower impairment charges - TradingView
INmune Bio (NASDAQ: INMB) posts $6.7M loss and warns on cash runway - Stock Titan
INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress - Yahoo Finance
INmune Bio Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
INmune Bio receives $4.6M in R&D rebates from Australia, UK - Investing.com UK
INmune Bio Strengthens Cash Runway With R&D Rebates - TipRanks
大文字化:
|
ボリューム (24 時間):